For more than two decades, Shire has demonstrated leadership in neuroscience through helping more patients, progressing our pipeline, and expanding into additional conditions. Misunderstanding of conditions like Attention-Deficit/Hyperactivity Disorder (ADHD), Binge Eating Disorder (B.E.D.), and epilepsy is widespread, which can add to the unique challenges people living with these conditions are already facing. Building awareness and understanding can remove some of the additional obstacles these people may encounter.

Weve built relationships with patient advocacy groups and organizations globally, and regularly share our expertise with physicians, patients, caregivers, and policymakers to raise awareness and broaden understanding of these conditions worldwide. We are also committed to helping combat the misuse, abuse, and diversion of ADHD medicines.

Our neuroscience division currently champions for the patients, parents, caregivers, and physicians who are touched by:

Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder that manifests as a persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development. It is a diverse condition that can have a significant impact on patients lives.5,6 ADHD is relatively common and often persists into adulthood.7,8,9,10 Only a trained healthcare professional can diagnose ADHD.

Once thought of as a childhood problem, ADHD persists into adulthood in 50-60% of people diagnosed as a child11,12,13,14 and affects around one in 30 (3.4%) adults worldwide.14

Binge Eating Disorder, or B.E.D., is a distinct medical condition recognized by the American Psychiatric Association.1 In the U.S., its more common than anorexia and bulimia combined,2,3* affecting an estimated 2.8 million adults.2,4 Although B.E.D. affects both men and women,2 research shows that twice as many women are affected.

Epilepsy is a condition characterized by recurrent epileptic seizures that arent provoked by an immediate identifiable cause.

S38370 03/18

Read more:
Neuroscience - shire.com